Abstract
Coxsackievirus strain CVB3 is widespread in the human population and causes myocarditis or pancreatitis. However, despite its clinical impact, there is no commercially available and clinically applicable prophylactic vaccine. This study examines the characteristics of attenuated CVB3 strains developed so far and their application as live-attenuated CVB3 vaccines, and discusses problems to be overcome in the development of live-attenuated vaccines.
Publication types
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
Animals
-
Antibodies, Viral / biosynthesis
-
Coxsackievirus Infections / immunology
-
Coxsackievirus Infections / prevention & control
-
Coxsackievirus Infections / virology
-
Enterovirus / genetics
-
Enterovirus / immunology*
-
Genetic Vectors
-
Humans
-
Mutation / genetics
-
Receptors, Virus / genetics
-
Vaccines, Attenuated / genetics
-
Vaccines, Attenuated / immunology*
Substances
-
Antibodies, Viral
-
Receptors, Virus
-
Vaccines, Attenuated
-
coxsackievirus B receptor